
201 - 500 employees
Founded 2017
🧬 Biotechnology
💊 Pharmaceuticals
🏥 Healthcare
💰 $125M Post-IPO Equity - Stoke Therapeutics on 2024-03
Biotechnology • Pharmaceuticals • Healthcare
Stoke Therapeutics is a biotechnology company developing RNA-based therapeutics that increase protein production from a patient’s own genes to treat rare genetic diseases. Its TANGO (Targeted Augmentation of Nuclear Gene Output) platform uses antisense oligonucleotides to upregulate gene expression in haploinsufficiency disorders. Lead programs include STK‑001, an antisense therapy in development for Dravet syndrome (SCN1A haploinsufficiency), and other programs focused on genetic neurology and rare disease indications.
🕒 July 29
Improve your chances of getting an interview by checking your resume score before you apply.

201 - 500 employees
Founded 2017
🧬 Biotechnology
💊 Pharmaceuticals
🏥 Healthcare
💰 $125M Post-IPO Equity - Stoke Therapeutics on 2024-03
Biotechnology • Pharmaceuticals • Healthcare
Stoke Therapeutics is a biotechnology company developing RNA-based therapeutics that increase protein production from a patient’s own genes to treat rare genetic diseases. Its TANGO (Targeted Augmentation of Nuclear Gene Output) platform uses antisense oligonucleotides to upregulate gene expression in haploinsufficiency disorders. Lead programs include STK‑001, an antisense therapy in development for Dravet syndrome (SCN1A haploinsufficiency), and other programs focused on genetic neurology and rare disease indications.
• Develop and execute pre-launch and launch-phase access strategies, establishing Stoke’s presence with key accounts. • Serve as strategic leader for key accounts in the region. • Develop account-specific action plans that shorten the timeline from FDA approval to an active, positive coverage determination. • Build payer relationships and establish Stoke’s credibility with medical benefit policy decision-makers before NDA submission, ensuring seamless coverage between approval and patient access. • Develop multi-year access plans that anticipate commercial cycles and competitive coverage shifts, balancing account-level execution with a national access strategy. • Educate payers on clinical evidence, FDA labeling, treatment guidelines, and health-economic data to support coverage decisions and eliminate utilization management barriers (step edits, PA criteria, NDC blocks). • Monitor medical policy language at each account and partner with Medical Affairs, HEOR, and Advocacy to respond to and proactively shape policy criteria. • Proactively engage payer Medical Directors to obtain informal guidance letters or billing instructions that bridge the gap between launch and permanent J code assignment. • Engage and influence policy decision-makers for a medical benefit product to achieve desired coverage policy outcomes. • Serve as the company’s subject-matter expert on buy-and-bill reimbursement dynamics for products carrying a miscellaneous J code (J3490/J3590) pending assignment of a permanent, product-specific J code. • Educate payer medical policy teams on correct claims submission procedures, billing unit conventions, and NDC-to-J code crosswalk requirements to minimize claim denials during the unclassified code period. • Drive alignment across Stoke’s commercial team and field medical team without direct reporting relationships, building internal coalitions across Medical, HEOR, Reimbursement, Government Affairs, Legal, Trade & Distribution, and Patient Services to ensure integrated execution. • Ensure effective communication and coordination between the field reimbursement team and patient services to support a high approval success rate and timely patient access. • Engage authentically with the Dravet syndrome patient and caregiver community and incorporate community insights into payer engagement in a compelling and compliant manner. • Conduct all payer engagements in full compliance with company SOPs, OIG guidelines, PhRMA Code, and applicable federal and state regulations. • Navigate the unique complexity of a first-in-class disease-modifying ASO therapy with no established coverage precedent, finding creative and compliant paths to access.
• Bachelor’s degree required; advanced degree (MBA, MPH, PharmD) preferred. • 15+ years in pharma/biotech; minimum 10 years in payer account management with lead responsibility for one of the three large PBM and National accounts. • Proven track record of achieving positive coverage outcomes for orphan designation or rare disease products on the medical benefit. • Pre-launch payer strategy experience—not just maintenance of established access. • Hands-on experience navigating a miscellaneous J code (J3490/J3590) environment, including transition to a permanent product-specific code. • Strong command of managed care economics, formulary management, utilization management, and coverage policy development processes at national payers. • Rare pediatric or neurological disease product launch experience; CNS or epilepsy payer experience a significant differentiator. • Familiarity with disease-modifying therapy and gene testing reimbursement pathways as established according to payer policy. • Experience at a company building its commercial infrastructure for the first time—startup or early commercial-stage biotech. • Exceptional ability to influence across functions without direct authority. • Passion for patient access and rare-disease impact.
• Medical, dental and vision insurance • Life, long- and short-term disability insurance • Paid parental leave • 401K plan with company match • Unlimited vacation time • Tuition assistance • Participation in our Employee Stock Purchase Program (ESPP)
Apply Now🕒 July 29
Electrical Associate Director leading design activities and overseeing staffing and capacity planning at DLB Associates. Driving organizational development and continuous improvement in engineering processes.
🕒 July 29
Division Associate Director leading engineering operations for DLB Associates, an engineering and consulting firm serving data centers and advanced infrastructure. Driving strategy, client programs, staffing, business development, and digital transformation across MEP consulting sectors.
🕒 July 29
Associate Director of BIM overseeing electrical design and BIM operations for DLB Associates. Leading strategic direction, quality assurance, and execution within all mechanical BIM operations.
🕒 July 29
51 - 200
Associate Director overseeing analytical development and quality control for Kailera's therapies. Collaborating cross-functionally to ensure drug development and manufacturing alignment with regulatory requirements.
🇺🇸 United States – Remote
💵 $155k - $190k / year
🔥 Funding within the last year
💰 $600M Series B - Kailera Therapeutics on 2025-10
⏰ Full Time
🟠 Senior
👔 Director
🕒 July 28
Associate Director for Government Affairs at Travere Therapeutics, driving policy strategies for rare disease treatments. Responsible for strategic leadership and stakeholder engagement in healthcare policy.